Added to YB: 2025-12-30
Pitch date: 2025-12-28
SLNO [bullish]
Soleno Therapeutics, Inc.
+10.86%
current return
Author Info
No bio for this author
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
Soleno Therapeutics, Inc., biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases.
Market Cap
$2.8B
Pitch Price
$47.80
Price Target
130.00 (+145%)
Dividend
N/A
EV/EBITDA
24.71
P/E
29.97
EV/Sales
8.02
Sector
Biotechnology
Category
growth
Show full summary:
Soleno Therapeutics (NASDAQ: SLNO)
SLNO: FDA-approved VYKAT XR for PWS hyperphagia shows strong Q3 launch w/ $66M revenue (vs $46M est), 764 treated patients, 8% discontinuation. Only approved therapy in 12-22K US PWS market. Weight-based dosing creates higher real-world revenues. $130 target on DCF, peak sales est $3.2B by 2033.
Read full article (43 min)